FLT3 and acute myeloid leukemia: However, there are few directly comparable data for the control arm of the QUANTUM-R trial, except for the UK NCRI AML15, AML16, and AML17 trials, which included a total of 264 FLT3-ITD AML patients with a median age of 51 years.